ECO 2025 - Findings from the RESET trial show early weight loss with an oral, shape-shifting, superabsorbent, hydrogel capsule was superior to placebo and predicted long-term success in patients with overweight and obesity.

Dr Donna Ryan (Pennington Biomedical, Baton Rouge, US) joins us to discuss findings from RESET (NCT04222322; Epitomee Medical). The prospective, randomised, double-blind, placebo-controlled trial investigated the effect of early weight loss with the Epitomee capsule in combination with lifestyle modification. Patients with overweight and obesity with and without prediabetes who were the best responders to the Epitomee capsule in a previous randomised clinical comparison were enrolled in the trial. The RESET trial aimed to identify the characteristics of these responders.

Interview Questions:
1. What is the background behind the RESET trial?
2. Could you tell us about the mechanism of action behind the Epitomee capsule?
3. What was the study design and patient population?
4. What are the key outcomes, and were there any surprising or unexpected results?
5. What are the take-home messages for practice?
6. What further research is needed in this area?

Recorded remotely from Baton Rouge, 2025.

Editors: Jordan Rance, Yazmin Sadik
Videographers: Oliver Miles, David Ben-Harosh

Support: This is an independent interview produced by Radcliffe CVRM.